Gene content    
TGFBR2 ( by HUGO)
Transforming Growth Factor, Beta Receptor II (70/80kDa)
Tumor suppressor gene
Transforming Growth Factor
Beta Receptor II (70/80kDa)
MFS2
TGFR-2
TGF-Beta Type II Receptor
EC 2.7.11.30
AAT3
Transforming Growth Factor
Beta Receptor II (70-80kD)
FAA3
LDS1B
LDS2B
RIIC
TAAD2
TGFbeta-RII
tbetaR-II
TGF-Beta Receptor Type IIB
TGF-Beta Receptor Type-2
Transforming Growth Factor Beta Receptor Type IIC
TbetaR-II
TGF-Beta Receptor Type II
Transforming Growth Factor-Beta Receptor Type II
HNPCC6
LDS2
EC 2.7.11
NCBI: 3p22    Ensembl: 3p24.1
TGFR2_HUMANSize: 567 amino acidsMass: 64568 Da

  • Subunit: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric ligands assemble a functional receptor composed of two TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate the kinetics of assembly of the receptor and may explain the different biological activities of TGFB1, TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta receptor. Interacts with and is activated by SCUBE3; this interaction does not affect TGFB1-binding to TGFBR2. Interacts with VPS39; this interaction is independent of the receptor kinase activity and of the presence of TGF-beta 5 PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for TGFBR2: 1KTZ (3D) [IMAGE] 1M9Z (3D) [IMAGE] 1PLO (3D) [IMAGE] 2PJY (3D) [IMAGE] 3KFD (3D) [IMAGE]
  • Function:
    Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways
                          
    Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways
  • Catalytic activity:
    ATP + [receptor-protein] = ADP + [receptor-protein] phosphate
  • Similarity:
    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily
                          
    Contains 1 protein kinase domain [IMAGE]
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR000333TGFB_receptorActivin type II receptorFamily
    IPR000719Prot_kinase_domProtein kinaseDomain
    IPR008271Ser/Thr_kinase_ASSerine/threonine protein kinase, active siteActive Sites
    IPR011009Kinase-like_domProtein kinase-likeDomain
    BlocksIPB000472Domain in TGF-beta receptor/activin receptorDomain in TGF-beta receptor/activin receptor, type I/II

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process apoptotic process IDA GOA 17471240
    blood vessel development TAS GOA 10092230
    pathway-restricted SMAD protein phosphorylation IDA GOA 11157754
    peptidyl-serine phosphorylation IDA GOA 12015308
    peptidyl-threonine phosphorylation IDA GOA 12015308
    positive regulation of cell proliferation TAS GOA 7761852
    protein phosphorylation IDA GOA 12015308
    response to cholesterol IDA GOA 17878231
    response to drug IDA GOA 17878231
    transforming growth factor beta receptor signaling pathway IC GOA 1326540
    transforming growth factor beta receptor signaling pathway IDA GOA 18453574
    transforming growth factor beta receptor signaling pathway IMP GOA 11157754
    Cellular Component caveola IDA GOA 17878231
    external side of plasma membrane IDA GOA 18453574
    integral component of membrane IDA GOA 7852346
    receptor complex IDA GOA 8774881
    transforming growth factor beta receptor homodimeric complex IC GOA 1326540
    Molecular Function contributes_to protein binding IPI GOA 11157754
    glycosaminoglycan binding IDA GOA 7852346
    protein binding IPI GOA 11157754
    SMAD binding IDA GOA 11157754
    transforming growth factor beta binding IPI GOA 1326540
    transforming growth factor beta binding IDA GOA 11157754
    transforming growth factor beta-activated receptor activity IMP GOA 1333888
    transforming growth factor beta-activated receptor activity IDA GOA 18453574
    transforming growth factor beta-activated receptor activity IC GOA 1326540
    transmembrane receptor protein serine/threonine kinase activity IDA GOA 12015308
    type I transforming growth factor beta receptor binding IPI GOA 1333888
    type I transforming growth factor beta receptor binding IDA GOA 11157754
    type III transforming growth factor beta receptor binding IDA GOA 11157754

    Disorder & Mutation    
    Source Disease
    SWISS-PROTEsophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTLoeys-Dietz syndrome 1B (LDS1B) [MIM:610168]: An aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTHereditary non-polyposis colorectal cancer 6 (HNPCC6) [MIM:614331]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=The disease is caused by mutations affecting the gene represented in this entry

    TGFBR2 cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene